Literature DB >> 21864608

Mitochondrial ERK plays a key role in δ-opioid receptor neuroprotection against acute mitochondrial dysfunction.

Min Zhu1, Mingwei Li, Fan Yang, Xiaomin Ou, Qingxiao Ren, Hui Gao, Cuiqing Zhu, Jingchun Guo.   

Abstract

It is well established that stimulating delta-opioid receptor (DOR) with its specific agonists elicits neuroprotection against hypoxia/ischemia. Mitochondrial dysfunction plays a key role in hypoxic neuronal injury, but the effects of DOR activation on mitochondrial dysfunction in neurons are poorly elucidated. In this investigation, we studied the effects of [D-Ala2, D-Leu5] enkephalin (DADLE), a potent DOR agonist, on acute mitochondrial dysfunction and ensuing cell damage induced by sodium azide in primary rat cortical neuronal cultures, and explored possible mechanisms underlying. Here, we show that DADLE reverses NaN(3)-induced acute mitochondrial dysfunction by selectively activating DOR, mainly including mitochondrial membrane depolarization, mitochondrial Ca(2+) overload and reactive oxygen species generation. DOR stimulation also inhibits cytochrome c release and caspase-3 activation, and attenuates neuronal death caused by acute NaN(3) insults. Furthermore, DOR activation with DADLE protects neurons from acute NaN(3) insults mainly through PKC-ERK pathway, and mitochondrial ERK activation is especially required for DOR neuroprotection against acute mitochondrial dysfunction. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864608     DOI: 10.1016/j.neuint.2011.08.005

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  8 in total

1.  Prolonged DADLE exposure epigenetically promotes Bcl-2 expression and elicits neuroprotection in primary rat cortical neurons via the PI3K/Akt/NF-κB pathway.

Authors:  Min Zhu; Ming Liu; Qi-Lin Guo; Cui-Qing Zhu; Jing-Chun Guo
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

Review 2.  Neuroprotection against hypoxia/ischemia: δ-opioid receptor-mediated cellular/molecular events.

Authors:  Xiaozhou He; Harleen K Sandhu; Yilin Yang; Fei Hua; Nathalee Belser; Dong H Kim; Ying Xia
Journal:  Cell Mol Life Sci       Date:  2012-09-27       Impact factor: 9.261

Review 3.  Delta opioid receptors in brain function and diseases.

Authors:  Paul Chu Sin Chung; Brigitte L Kieffer
Journal:  Pharmacol Ther       Date:  2013-06-10       Impact factor: 12.310

4.  Mu-opioid receptor and delta-opioid receptor differentially regulate microglial inflammatory response to control proopiomelanocortin neuronal apoptosis in the hypothalamus: effects of neonatal alcohol.

Authors:  Pallavi Shrivastava; Miguel A Cabrera; Lucy G Chastain; Nadka I Boyadjieva; Shaima Jabbar; Tina Franklin; Dipak K Sarkar
Journal:  J Neuroinflammation       Date:  2017-04-14       Impact factor: 8.322

Review 5.  The Opioid System in Temporal Lobe Epilepsy: Functional Role and Therapeutic Potential.

Authors:  Johannes Burtscher; Christoph Schwarzer
Journal:  Front Mol Neurosci       Date:  2017-08-07       Impact factor: 5.639

6.  Proenkephalin Derived Peptides Are Involved in the Modulation of Mitochondrial Respiratory Control During Epileptogenesis.

Authors:  Johannes Burtscher; Camilla Bean; Luca Zangrandi; Iwona Kmiec; Alexandra Agostinho; Luca Scorrano; Erich Gnaiger; Christoph Schwarzer
Journal:  Front Mol Neurosci       Date:  2018-09-25       Impact factor: 5.639

Review 7.  Spoken and Unspoken Matters Regarding the Use of Opioids in Cancer.

Authors:  Janna Baker Rogers; Gerald M Higa
Journal:  J Pain Res       Date:  2022-04-05       Impact factor: 3.133

8.  Delta Opioid Receptor Activation with Delta Opioid Peptide [d-Ala2, d-Leu5] Enkephalin Contributes to Synaptic Improvement in Rat Hippocampus against Global Ischemia.

Authors:  Guangming Zhang; Zelin Lai; Lingling Gu; Kejia Xu; Zhenlu Wang; Yale Duan; Huifen Chen; Min Zhang; Jun Zhang; Zheng Zhao; Shuyan Wang
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.